Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received December 22, 2016
- Revision received December 21, 2016
- Accepted March 7, 2017
- Published first March 13, 2017.
Article Versions
- Previous version (March 13, 2017 - 06:11).
- You are currently viewing a Previous version of this article (May 18, 2017 - 06:38).
- View the most recent version of this article
Copyright & Usage
©2017 American Association for Cancer Research.
Author Information
- Toshimitsu Yamaoka1,*,
- Tohru Ohmori1,
- Motoi Ohba1,
- Satoru Arata1,2,
- Yasunori Murata3,
- Sojiro Kusumoto3,
- Koichi Ando3,
- Hiroo Ishida4,
- Tsukasa Ohnishi3, and
- Yasutsuna Sasaki4
- 1Institute of Molecular Oncology, Showa University, Tokyo, Japan.
- 2Center for Biotechnology, Showa University, Tokyo, Japan.
- 3Division of Allergology and Respiratory Medicine, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
- 4Division of Clinical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
- ↵*Corresponding Author:
Toshimitsu Yamaoka, Institute of Molecular Oncology, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan. Phone: 81-33784-8146; Fax: 81-33784-2299; E-mail: yamaoka.t{at}med.showa-u.ac.jp
Published OnlineFirst May 18, 2017
doi: 10.1158/1541-7786.MCR-16-0482
Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation
Jump to section
Advertisement